Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
by eazee-designstudio
Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
Data from a randomized, multi-center, 170 patient Phase II study with resminostat as first-line treatment of advanced liver cancer presented at 2017 Gastrointestinal Cancers Symposium shows substantial increase in overall survival
iOmx Therapeutics raises EUR 40 million in Series A round led by MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
Themis Bioscience: Zika Vaccine Development Receives Big Boost by Innovate UK
Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus.
Austrian biotech company Themis Bioscience said it had started a clinical trial of an experimental Zika vaccine in healthy volunteers.
To advance novel RIG-I targeted immuno-oncology therapeutics. The company also announced opening of Cambridge, MA office.
Promising scientific data open up new therapeutic combination options for the epigenetic anti-cancer compound resminostat.
NEUWAY Receives €2.95 Million BMBF Grant for Advancing CNS Drug Delivery Platform. CLICK FOR MORE.
